Incidence of Mucocutaneous Adverse Events Using Actual Versus Adjusted Body Weight Dosing in Obese Patients Undergoing Autologous HSCT With Etoposide- or Melphalan-Based Conditioning Chemotherapy
Related Items
JHOP - October 2026 Vol 16, No 5 published on September 21, 2026 in Original Research, Adverse Events, Transplant, Drug Resistance, Oncology Pharmacy Programs/Protocols
JHOP - October 2026 Vol 16, No 5 published on September 21, 2026 in Original Research, Adverse Events, Disparities in Oncology Care, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma
JHOP - October 2026 Vol 16, No 5 published on September 21, 2026 in Original Research, Lymphoma, Methotrexate, Chemotherapy